ACP
AZN icon

Acuta Capital Partners’s AstraZeneca AZN Stock Holding History

Acuta Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-15,000
Closed -$986K – 56
2016
Q3 		$986K Buy
+15,000
New +$980K 0.37% 46

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Acuta Capital Partners's AZN Position: Q4 2016 in Review

Acuta Capital Partners sold out of AstraZeneca (AZN) in Q4 2016, closing a stake of 15,000 shares — an estimated $986K sold.

Acuta Capital Partners first reported a position in AZN in Q3 2016 and held it in 1 quarter. The position peaked at $986K in Q3 2016. 450 funds tracked by Wall St. Rank hold AZN as of Q4 2016.

  • Acuta Capital Partners reported no remaining AstraZeneca position as of Q4 2016 after selling out during the quarter.
  • Acuta Capital Partners sold 15,000 AstraZeneca shares in Q4 2016, an estimated $986K.
  • Acuta Capital Partners first reported a position in AstraZeneca in Q3 2016 and held it in 1 quarter.
  • Acuta Capital Partners's AstraZeneca position peaked at $986K in Q3 2016.
  • 450 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2016.

Based on Acuta Capital Partners's 13F filing for Q4 2016, filed 13 Feb 2017.